SUBSCRIBE
SUBSCRIBE

Lung cancer

Pictured: 3D illustration of antibody-drug conjugates with their toxic payloads
Job Trends
Daiichi Sankyo Drops $1B to Boost ADC Manufacturing Capacity at German Site
With the investment in the plant, Daiichi Sankyo is looking to create new laboratories for its antibody-drug conjugates used to develop and manufacture therapies for breast, lung and stomach cancers.
February 20, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: AstraZeneca signage at its office in Sweden
Drug Development
AstraZeneca’s Tagrisso Continues NSCLC Streak with New Phase III Data
In a late-stage study, Tagrisso induced a “statistically significant and highly clinically meaningful improvement” in progression-free survival in patients with unresectable stage III, EGFR-mutated non-small cell lung cancer.
February 20, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Exterior of an FDA building
Policy
FDA Accepts BLA for AstraZeneca, Daiichi Sankyo’s ADC for NSCLC
The companies’ Biologics License Application for antibody-drug conjugate datopotamab deruxtecan has been accepted by the FDA for locally advanced or metastatic nonsquamous non-small cell lung cancer.
February 19, 2024
 · 
2 min read
 · 
Tyler Patchen
AstraZeneca's sign on its office in California
FDA
AstraZeneca Expands Tagrisso’s NSCLC Label, FDA Allows Use with Chemo
The regulator’s approval means AstraZeneca’s Tagrisso can now be used in combination with chemotherapy for locally advanced or metastatic EGFR-mutated non-small cell lung cancer patients.
February 19, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
PRESS RELEASES
Press Releases
MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer
December 3, 2024
 · 
6 min read
Press Releases
FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutations
December 3, 2024
 · 
19 min read
Press Releases
Aulos Bioscience Doses First Patient in Phase 2 Cohort Evaluating the Combination of Avelumab and AU-007 for the Treatment of Non-Small Cell Lung Cancer
November 27, 2024
 · 
4 min read
Press Releases
Delta-Fly Pharma Inc.: Progress Update of the Phase III Clinical Trial of DFP-14323
November 26, 2024
 · 
1 min read
Press Releases
Alpha Biopharma received NMPA approval for Zorifertinib Tablets (Zorifer®), the world’s first EGFR-TKI for lung cancer with brain metastases.
November 20, 2024
 · 
5 min read
Press Releases
DELFI Diagnostics Selects Lahey Hospital & Medical Center to Administer New Lung Cancer Screening Test
November 20, 2024
 · 
2 min read
Press Releases
Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer
November 19, 2024
 · 
5 min read
Press Releases
Novotech Releases Comprehensive Report on the Global Clinical Trial Landscape for Small Cell Lung Cancer (SCLC)
November 18, 2024
 · 
2 min read
Press Releases
U.S. Food and Drug Administration Approves FoundationOne®Liquid CDx as a Companion Diagnostic for TEPMETKO® (tepotinib) to Identify Patients with MET Exon 14 Skipping Alterations in Non-Small Cell Lung Cancer
November 18, 2024
 · 
4 min read
Press Releases
CHMP recommends RYBREVANT®▼ (amivantamab) in combination with LAZCLUZE®▼ (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer
November 15, 2024
 · 
16 min read
Press Releases
Cofactor Genomics expands clinical use of OncoPrism, as their AI enabled RNA test achieves national clinical validation after predicting immunotherapy response in Lung Cancer Patients
November 15, 2024
 · 
2 min read
Press Releases
Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
November 15, 2024
 · 
18 min read
Press Releases
Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
November 15, 2024
 · 
5 min read
Press Releases
Angle PLC Announces Parsortix Based PD-L1 Assay Showcased at AACR
November 15, 2024
 · 
5 min read
Press Releases
Biofidelity launches Aspyre® Lung Reagents, now enabling integrated tissue and liquid biopsy analysis
November 15, 2024
 · 
2 min read
Press Releases
Angle PLC Announces Parsortix enriched CTC & ctDNA in NSCLC patients
November 11, 2024
 · 
5 min read
Press Releases
Dizal Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
November 8, 2024
 · 
5 min read
Press Releases
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study
November 8, 2024
 · 
9 min read
Press Releases
Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 7, 2024
 · 
8 min read
Press Releases
Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer
November 5, 2024
 · 
10 min read
Load More